Haemonetics Co. (NYSE:HAE) Short Interest Update

Haemonetics Co. (NYSE:HAE - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 5,240,000 shares, an increase of 5.6% from the January 15th total of 4,960,000 shares. Based on an average daily volume of 781,800 shares, the days-to-cover ratio is presently 6.7 days. Currently, 10.6% of the company's shares are sold short.

Haemonetics Trading Down 0.7 %

Haemonetics stock traded down $0.47 during mid-day trading on Friday, hitting $62.98. The company's stock had a trading volume of 986,273 shares, compared to its average volume of 1,030,576. The company has a 50 day moving average of $72.61 and a 200-day moving average of $76.66. The stock has a market cap of $3.16 billion, a PE ratio of 24.79, a P/E/G ratio of 1.11 and a beta of 0.39. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. Haemonetics has a one year low of $58.80 and a one year high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, research analysts anticipate that Haemonetics will post 4.55 EPS for the current year.

Institutional Investors Weigh In On Haemonetics

Hedge funds have recently made changes to their positions in the company. TD Waterhouse Canada Inc. purchased a new stake in shares of Haemonetics in the 4th quarter worth $25,000. Covestor Ltd lifted its holdings in shares of Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after buying an additional 439 shares during the period. Whittier Trust Co. purchased a new stake in shares of Haemonetics in the 4th quarter worth $62,000. Nisa Investment Advisors LLC lifted its holdings in shares of Haemonetics by 124.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 632 shares during the period. Finally, Parkside Financial Bank & Trust lifted its holdings in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on HAE. JPMorgan Chase & Co. began coverage on Haemonetics in a research report on Friday, December 6th. They set an "overweight" rating and a $116.00 target price on the stock. JMP Securities cut their target price on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research report on Friday, February 7th. StockNews.com downgraded Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Raymond James reissued a "strong-buy" rating and set a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Finally, Needham & Company LLC cut their target price on Haemonetics from $112.00 to $108.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $101.67.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.